All In Biotech

Drug Trial Radar · NCT01614990

Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia

Last checked: Nov 20, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

May 2012

Primary completion

Jul 2020

Study completion Dec 2021

Sponsor

Lead sponsor
Garcia, Jose M., MD, PhDIndividual
Sponsor type
Individual
Collaborators
VA Office of Research and Development; Baylor College of Medicine; AEterna Zentaris
First posted
Jun 8, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.

Conditions

  • Cancer Cachexia

Interventions

  • MacimorelinDrug

    Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.

  • PlaceboDrug

    placebo (Powerade®) daily for 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of Body WeightTime frame: 7 days
  2. Change of Insulin-like Growth Factor-1 (IGF-1) Plasma LevelsTime frame: 7 days
  3. Change of Quality of Life ScoreTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Veterans Affairs Puget Sound Health Care System

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.